RxDoctor Payments Data

Dan Chaksupa, MD

Internal Medicine · Raleigh, NCNPI 1992819676

Payments from drug & device makers

$7,590in general payments, 2019–2025

Across 495 payments — averaging $15.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Amgen$666
  • AbbVie$572
  • Lilly USA, LLC$564
  • AstraZeneca$453
  • Boehringer Ingelheim$377
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$7,590100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,590 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$149,983
Medicare patients
251
Services billed
4,827

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide164$184,908
JardianceEmpagliflozin81$76,216
EliquisApixaban54$55,954
MounjaroTirzepatide35$40,104
XareltoRivaroxaban27$38,530
OzempicSemaglutide41$38,295
JanuviaSitagliptin Phosphate25$32,331
JanumetSitagliptin Phos/Metformin Hcl22$22,971
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$21,141
MyrbetriqMirabegron31$17,488
Tresiba Flextouch U-100Insulin Degludec27$13,121
Soliqua 100-33Insulin Glargine/Lixisenatide13$11,084
Breo ElliptaFluticasone/Vilanterol22$8,411
Arnuity ElliptaFluticasone Furoate27$7,297
Meprobamate12$6,989

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$564$225,012199 claims
Boehringer IngelheimJardiance$377$76,21681 claims
PfizerEliquis, Paxlovid$210$60,24176 claims
MerckJanuvia, Janumet$186$55,30247 claims
Johnson & JohnsonXarelto$239$38,53027 claims
Novo NordiskOzempic$2,012$38,29541 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$114$36,84875 claims
Astellas Pharma US IncMyrbetriq$192$17,48831 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$201$11,08413 claims
AbbVieSynthroid$572$1,92732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →